Elite Pharmaceuticals Inc (ELTP): Administered intravenously--huge added e...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Tuesday, 07/08/2014 8:06:09 PM

Tuesday, July 08, 2014 8:06:09 PM

Administered intravenously--huge added expense, unpleasant experience and extremely inconvenient for ongoing use.

Keep Last Read

Replies (1) Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:07:15 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:30:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:55:26 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 07:21:28 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:20:29 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:20:20 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 12:05:38 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:58:46 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:50:54 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 08:15:15 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 09:30:05 PM
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/31/2023 08:20:27 PM

InvestorsHub NewsWire

Only $200 per official company press release!